

UPDATE: COVID-19 Therapies

November 23, 2020

Dear Valued Customer,

As the situation continues to evolve regarding the COVID-19 pandemic, AmerisourceBergen remains committed to providing relevant and timely updates to you, our customer. Recently the U.S. Food and Drug Administration (FDA) has granted approval and/or Emergency Use Authorizations for several COVID-19 therapies, and we wanted to take this time to provide a cohesive update on the four available therapies.

AVAILABLE THERAPIES

Product	Manufacturer	Commercially Available?	Government Allocated?	NDC # (if commercially available)	ABC Item # (if commercially available)
Veklury (remdesivir)	Gilead Sciences	YES*	NO	61958-2901-02	10251685
Bamlanivimab	Eli Lilly and Company	NO**	YES	N/A	N/A
Olumiant (baricitinib)	Eli Lilly and Company	YES*	NO	2mg: 0002-4182-30 1mg: 0002-4732-30	2mg: 10251952 1mg: 10252013
Casirivimab and Imdevimab	Regeneron Pharmaceuticals, Inc.	NO**	YES	N/A	N/A

ORDERING INFORMATION

Product	Can I order directly from ABC?	If yes, how?	If no, how do I get product?
Veklury (remdesivir)	Yes*	Through AmerisourceBergen Ordering Platforms, by emailing remdesivir@amerisourcebergen.com or contacting your Account Executive or Account Experience Liaison	N/A
Bamlanivimab	No**	N/A	HHS, ASPR & State DOH's are allocating product. If you have been chosen to receive product ABC will reach out to you directly. If you have not been allocated product, reach out directly to your State Department of Health to request allocation.
Olumiant (baricitinib)	Yes*	Through AmerisourceBergen Ordering Platforms or contacting your Account Executive or Account Experience Liaison.	N/A
Casirivimab and Imdevimab	No**	N/A	HHS, ASPR & State DOH's are allocating product. If you have been chosen to receive product ABC will reach out to you directly. If you have not been allocated product, reach out directly to your State Department of Health to request allocation.

UPDATE: COVID-19 Therapies

November 23, 2020

ADDITIONAL INFORMATION & RESOURCES

Product	FDA Approval OR EUA Announcement	Healthcare Providers Fact Sheet	Patient Fact Sheet	FDA Authorization Letter	Additional Info regarding product access, dosage, clinical data
Veklury (remdesivir)	FDA Approval	Healthcare Providers Resources	Patient Support	FDA Authorization Letter	Veklury Website
Bamlanivimab	EUA Announcement	Healthcare Providers Fact Sheet	Patient Fact Sheet (ENG) Patient Fact Sheet (SPA)	FDA Authorization Letter	Bamlanivimab Website
Olumiant (baricitinib)	EUA Announcement	Healthcare Providers Fact Sheet	Patient Fact Sheet (ENG) Patient Fact Sheet (SPA)	FDA Authorization Letter	Baricitinib Website
Casirivimab - Imdevimab	EUA Announcement	Healthcare Providers Fact Sheet	Patient Fact Sheet	FDA Authorization Letter	Casirivimab - Imdevimab Website

* For commercially available products, you can order directly from AmerisourceBergen through its specialty distribution services using the NDC and ABC Item Numbers listed above.

** For government allocated products, AmerisourceBergen will facilitate the distribution of all product to sites of care per direction from the U.S. Government and state Departments of Health, even if the site of care is not an AmerisourceBergen customer. To be clear, neither AmerisourceBergen nor the manufacturers control which sites of care across the country will receive this product.

If approved to receive bamlanivimab and/or casirivimab and imdevimab, a representative from AmerisourceBergen will reach out directly to your site(s) of care via phone or email to inform you that you are approved to receive the allocated product. If you have been designated as auto-ship by your respective state Department of Health, product will be auto-shipped to your site(s) of care. The AmerisourceBergen representative will provide your site(s) of care with information on how to receive and store product.

If your site(s) of care has not been allocated bamlanivimab and/or casirivimab and imdevimab, and you would like to receive an allocation of product, you should contact your state Health Department to indicate interest in receiving future allocation.

If your site(s) of care has been allocated to receive product, but has not been contacted by AmerisourceBergen, please reach out directly to bamlanivimab@amerisourcebergen.com or c19therapies@amerisourcebergen.com.

UPDATE: COVID-19 Therapies

November 23, 2020

Additional Questions/Inquiries

- For any questions not answered above, please reach out to your AmerisourceBergen Account Executive or Account Experience Liaison.
- If you are not sure who that contact is, please contact solutions@amerisourcebergen.com and we will get you in contact with your representative.
- If you are not an AmerisourceBergen customer, please contact c19therapies@amerisourcebergen.com for assistance.

As always, we remain committed to providing you with the most up-to-date and relevant information.

Thank you,
Your AmerisourceBergen Team